TQB3142 / Sino Biopharm - LARVOL DELTA

TQB3142, a clinical-stage BCL-XL PROTAC, demonstrates robust in vivo antitumor activity and a favorable pharmacokinetic profile as a potential best-in-class therapeutic (EORTC-NCI-AACR 2026) - "Abstract will be available as of 4 November (with consent of the author)"

PK/PD data • Preclinical • Oncology • BCL2L1

To Evaluate the Tolerability and Pharmacokinetics of TQB3142 for Injection in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=66 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

To Evaluate the Tolerability and Pharmacokinetics of TQB3142 for Injection in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=66 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

New P1 trial • Solid Tumor

APPLICATION FOR CLINICAL TRIAL OF TQB3142 “BcL-xL PROTAC” ACCEPTED BY NMPA (HKEXnews) - "...Sino Biopharmaceutical Limited...announces that the Investigational New Drug (IND) application for TQB3142 'Bcl-xL PROTAC (proteolysis targeting chimera)', an innovative drug intended for the treatment of malignant tumors independently developed by the Group has been accepted by the National Medical Products Administration of China (NMPA)."

New trial • Oncology

Two new Class 1 anti-tumor drugs from Sinopharm have been accepted for clinical trials for the first time [Google translation] (Sino Biopharm Press Release) - "Recently, the National Medical Products Administration (NMPA) accepted the new drug clinical trial applications (INDs) for...TQB3142 for injection (Bcl-xL PROTAC drug)....intended for the treatment of malignant tumors."

New trial • Solid Tumor